We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Life Sciences/The Challenge of Diagnosis and Indication for Treatment in Fabry Disease

Checking your access to this record.

Abstract & Overview

Fabry disease, caused by deficient alpha-galactosidase A lysosomal enzyme activity, remains challenging to health-care professionals. Laboratory diagnosis in males is carried out by determination of alpha-galactosidase A activity; for females, enzymatic activity determination fails to detect the disease in about two-thirds of the patients, and only the identification of a pathogenic mutation in the GLA gene allows for a definite diagnosis. The hurdle to be overcome in this field is to determine whether a mutation that has never been described determines a “classic” or “nonclassic” phenotype, because this will have an impact on the decision-making for treatment initiation. Besides the enzymatic determination and GLA gene mutation determination, researchers are still searching for a good biomarker, and it seems that plasma lyso-Gb3 is a useful tool that correlates to the degree of substrate storage in organs. The ideal time for treatment initiation for children and nonclassic phenotype remains unclear.

Cite this record

Marco A. Curiati, Carolina Sánchez Aranda, Sandra Obikawa Kyosen, Patrícia Varela, Vanessa Gonçalves Pereira, Vânia D’Almeida, et al. (2017). The Challenge of Diagnosis and Indication for Treatment in Fabry Disease. Journal of Inborn Errors of Metabolism and Screening, 5, 232640981668573–232640981668573. https://doi.org/10.1177/2326409816685735

Copy in another style

Curiati, M. A., Aranda, C. S., Kyosen, S. O., Varela, P., Pereira, V. G., D’Almeida, V., Pesquero, J. B., & Martins, A. M. (2017). The Challenge of Diagnosis and Indication for Treatment in Fabry Disease. Journal of Inborn Errors of Metabolism and Screening, 5, 232640981668573–232640981668573. https://doi.org/10.1177/2326409816685735
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.